Delivery Order SPE2DR25D1106-SPE2DR26FJB6E
- Not listed
- The Defense Logistics Agency (DLA) awarded a $34,394.28 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 5, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors, valued at $43,477.39 with a firm fixed price structure. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $12,741.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on December 2, 2025, with a completion date of December 3, 2025. This non-competitive, firm fixed-price delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Dupixent 300 mg/2 mL pen injectors on December 5, 2025, with a ceiling value of $33,461.78 and completion deadline of December 8, 2025. This competitive award, issued under firm fixed price terms with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $91,242.43 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on December 11, 2025, with an ultimate completion date of December 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors with a firm fixed price ceiling value of $24,740.80 and an ultimate completion date of December 2, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The award is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $19,202.22. The contract, executed on October 27, 2025, with an ultimate completion date of October 28, 2025, utilizes firm fixed pricing under a competitive, non-set-aside arrangement. Performance will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,036.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 2, 2025, with completion scheduled for June 3, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical procurement through the DLA's medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FJB6EDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $8,756.64 and a completion date of December 2, 2025. This competitive, non-set-aside delivery order reflects the company's role as a critical pharmaceutical supplier within the federal medical procurement system. The award is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle that extends through December 2026 and enables the company to supply an extensive range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Dupixent, a specialty pharmaceutical treatment, exemplifies the company's capability to fulfill federal medical supply needs through open competition and firm fixed pricing arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 11/30/25 |